A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial

BACKGROUND. Pegfilgrastim is widely used for the prevention of chemotherapy-induced neutropenia. In highly regulated markets, there are currently no approved biosimilars of pegfilgrastim. Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2) was a co...

Descripción completa

Detalles Bibliográficos
Autores principales: Blackwell, Kimberly, Donskih, Roman, Jones, C. Michael, Nixon, Allen, Vidal, Maria J., Nakov, Roumen, Singh, Pritibha, Schaffar, Gregor, Gascón, Pere, Harbeck, Nadia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2016
Materias:
Breast Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4943394/
https://www.ncbi.nlm.nih.gov/pubmed/27091420
http://dx.doi.org/10.1634/theoncologist.2016-0011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4943394/
https://www.ncbi.nlm.nih.gov/pubmed/27091420
http://dx.doi.org/10.1634/theoncologist.2016-0011

Ejemplares similares